Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M. Gay, Lauren A. Byers, C. Allison Stewart et al.|Cancer Cell|2021Cited by 930
Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic FeaturesLuisa M. Solis, Ignacio I. Wistuba|Clinical Cancer Research|2010Cited by 422
PI4KIIIβ is a therapeutic target in chromosome 1q–amplified lung adenocarcinomaXiaochao Tan, Jonathan M. Kurie, Priyam Banerjee et al.|Science Translational Medicine|2020Cited by 68
Augmented Lipocalin-2 Is Associated with Chronic Obstructive Pulmonary Disease and Counteracts Lung Adenocarcinoma DevelopmentWarapen Treekitkarnmongkol, Humam Kadara, Maya Hassane et al.|American Journal of Respiratory and Critical Care Medicine|2020Cited by 46
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Luisa M. Solis|Cancer Immunology Immunotherapy|2021Cited by 29